PE20191755A1 - Derivados de pirazol como inhibidores de malt 1 - Google Patents
Derivados de pirazol como inhibidores de malt 1Info
- Publication number
- PE20191755A1 PE20191755A1 PE2019001288A PE2019001288A PE20191755A1 PE 20191755 A1 PE20191755 A1 PE 20191755A1 PE 2019001288 A PE2019001288 A PE 2019001288A PE 2019001288 A PE2019001288 A PE 2019001288A PE 20191755 A1 PE20191755 A1 PE 20191755A1
- Authority
- PE
- Peru
- Prior art keywords
- naphthalen
- trifluoromethyl
- fluoro
- inhibitors
- pyrazole
- Prior art date
Links
- 229940122339 MALT1 inhibitor Drugs 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100038732 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Human genes 0.000 abstract 3
- 101710172604 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Proteins 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 abstract 1
- -1 2H-1,2,3-triazol-2-yl Chemical group 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- DUWRGQCQBXGPHA-UHFFFAOYSA-N N-(2-cyanopyridin-4-yl)-1-naphthalen-1-yl-5-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C(#N)C1=NC=CC(=C1)NC(=O)C=1C=NN(C=1C(F)(F)F)C1=CC=CC2=CC=CC=C12 DUWRGQCQBXGPHA-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437384P | 2016-12-21 | 2016-12-21 | |
| PCT/US2017/067516 WO2018119036A1 (en) | 2016-12-21 | 2017-12-20 | Pyrazole derivatives as malt1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191755A1 true PE20191755A1 (es) | 2019-12-12 |
Family
ID=61628454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001288A PE20191755A1 (es) | 2016-12-21 | 2017-12-20 | Derivados de pirazol como inhibidores de malt 1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10954214B2 (enExample) |
| EP (1) | EP3558969B1 (enExample) |
| JP (1) | JP7138641B2 (enExample) |
| KR (1) | KR102583317B1 (enExample) |
| CN (1) | CN110214136A (enExample) |
| AR (1) | AR110421A1 (enExample) |
| AU (2) | AU2017382185C1 (enExample) |
| BR (1) | BR112019012355A2 (enExample) |
| CA (1) | CA3048027A1 (enExample) |
| CL (1) | CL2019001709A1 (enExample) |
| CO (1) | CO2019006622A2 (enExample) |
| EA (1) | EA201991503A1 (enExample) |
| ES (1) | ES2992411T3 (enExample) |
| IL (1) | IL267343B2 (enExample) |
| MA (1) | MA47125A (enExample) |
| MX (2) | MX392673B (enExample) |
| PE (1) | PE20191755A1 (enExample) |
| PH (1) | PH12019501212A1 (enExample) |
| TN (1) | TN2019000192A1 (enExample) |
| TW (1) | TWI795381B (enExample) |
| UA (1) | UA127920C2 (enExample) |
| UY (1) | UY37537A (enExample) |
| WO (1) | WO2018119036A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| CA3009474A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| RS65576B1 (sr) | 2017-11-24 | 2024-06-28 | Jubilant Episcribe Llc | Heterociklična jedinjenja kao inhibitori prmt5 |
| KR20200105678A (ko) | 2017-12-28 | 2020-09-08 | 더 제너럴 하스피탈 코포레이션 | Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함 |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| AU2019289223B2 (en) * | 2018-06-18 | 2023-09-21 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
| EA202190055A1 (ru) * | 2018-06-18 | 2021-04-23 | Янссен Фармацевтика Нв | Производные пиразола в качестве ингибиторов malt1 |
| TW202045008A (zh) * | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
| EP3927324A1 (en) | 2019-02-22 | 2021-12-29 | Janssen Pharmaceutica NV | Pharmaceutical formulations |
| BR112021016400A2 (pt) * | 2019-02-22 | 2021-10-13 | Janssen Pharmaceutica N.V. | Forma cristalina de mono-hidrato de 1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil.)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida |
| US12404260B2 (en) | 2019-04-11 | 2025-09-02 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as MALT1 inhibitors |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| WO2021080015A1 (en) * | 2019-10-24 | 2021-04-29 | Ono Pharmaceutical Co., Ltd. | Modulators of trek (twik related k+ channels) channel function |
| ES3055177T3 (en) * | 2019-10-30 | 2026-02-10 | Biogen Ma Inc | Condensed pyridazine or pyrimidine as btk inhibitors |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CA3162140A1 (en) | 2019-11-22 | 2021-05-27 | Janssen Pharmaceutica Nv | Methods for assessing efficacy of malt1 inhibitors using an nf-kb translocation assay |
| KR20220119037A (ko) | 2019-11-22 | 2022-08-26 | 얀센 파마슈티카 엔.브이. | MALT1 억제제의 효능 평가를 위한 NF-kB 조절 유전자 발현 분석 |
| WO2021138298A1 (en) * | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| US20230235077A1 (en) | 2020-06-24 | 2023-07-27 | The General Hospital Corporation | Materials and methods of treating cancer |
| JP2023539729A (ja) * | 2020-08-21 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤の非晶質形態及びその製剤 |
| EP4199911A1 (en) * | 2020-08-21 | 2023-06-28 | JANSSEN Pharmaceutica NV | Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acid |
| WO2022081967A1 (en) * | 2020-10-16 | 2022-04-21 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| JP2023549835A (ja) * | 2020-11-12 | 2023-11-29 | モノプテロス セラピューティクス，インコーポレーテッド | がんを治療する材料及び方法 |
| GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| WO2022167962A1 (en) * | 2021-02-04 | 2022-08-11 | Aurigene Discovery Technologies Limited | Substituted pyrazolyl compounds as malt-1 inhibitors |
| EP4301365A1 (en) * | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| KR20230154227A (ko) | 2021-03-03 | 2023-11-07 | 얀센 파마슈티카 엔브이 | 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법 |
| CN117120427B (zh) * | 2021-06-18 | 2026-07-21 | 上海拓界生物医药科技有限公司 | 一种malt1抑制剂及其制备方法和用途 |
| EP4368618A1 (en) * | 2021-07-05 | 2024-05-15 | Betta Pharmaceuticals Co., Ltd | Six-membered aryl or heteroaryl amides, and composition and use thereof |
| CN117715898A (zh) * | 2021-07-05 | 2024-03-15 | 贝达药业股份有限公司 | 六元芳基或杂芳基酰胺类化合物及其组合物和用途 |
| WO2023016995A1 (en) | 2021-08-09 | 2023-02-16 | Janssen Pharmaceutica Nv | Compositions for use in treating b-cell malignancies |
| CN113912511B (zh) * | 2021-11-29 | 2024-02-13 | 广东广康生化科技股份有限公司 | 一种联苯肼酯中间体的合成方法 |
| JP2025501056A (ja) * | 2021-12-30 | 2025-01-17 | シャンハイ ハンソー バイオメディカル カンパニー リミテッド | 三環系誘導体阻害剤、その製造方法と応用 |
| KR20240144146A (ko) | 2022-02-02 | 2024-10-02 | 오노 야꾸힝 고교 가부시키가이샤 | Malt1 저해약을 유효 성분으로서 포함하는 암 치료제 |
| CN119095837A (zh) * | 2022-02-03 | 2024-12-06 | 希四克斯探索有限公司 | 作为malt1抑制剂的杂环衍生物 |
| TW202425968A (zh) * | 2022-08-26 | 2024-07-01 | 美商熱點醫療公司 | 吡唑基磺醯胺化合物及其在療法中之用途 |
| TW202430031A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| JP2025539452A (ja) | 2022-11-30 | 2025-12-05 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺微生物テトラヒドロイソキノリン誘導体 |
| CN118206543A (zh) * | 2022-12-15 | 2024-06-18 | 江苏恒瑞医药股份有限公司 | 一种苯并[c][1,2,5]噁二唑化合物的结晶形式及其制备方法 |
| CN118206538A (zh) * | 2022-12-15 | 2024-06-18 | 江苏恒瑞医药股份有限公司 | 一种苯并[c][1,2,5]噁二唑化合物与酒石酸复合物及其晶型 |
| CN120418243A (zh) * | 2022-12-16 | 2025-08-01 | 江苏恒瑞医药股份有限公司 | 一种Malt1抑制剂的磷酸酯前药 |
| TW202515550A (zh) * | 2023-06-29 | 2025-04-16 | 大陸商上海翰森生物醫藥科技有限公司 | 三并環類抑制劑與抗癌劑在製備抗腫瘤藥物中的聯合應用 |
| TW202515873A (zh) * | 2023-06-29 | 2025-04-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種三并環類衍生物抑制劑的晶型及其製備方法 |
| WO2025069270A1 (ja) * | 2023-09-27 | 2025-04-03 | 日本新薬株式会社 | アザインドール化合物及び医薬 |
| AU2024357109A1 (en) | 2023-10-06 | 2026-03-12 | Ionctura Sa | Combination of roginolisib with a malt1-gls inhibitor |
| WO2025114167A1 (en) | 2023-11-28 | 2025-06-05 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025174889A1 (en) * | 2024-02-13 | 2025-08-21 | Board Of Regents, The University Of Texas System | Malt1 and btk dual inhibitors |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025210095A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline compounds |
| WO2025210096A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Fungicidal compositions |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| GB9721964D0 (en) * | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| EP1622571A4 (en) * | 2003-04-30 | 2012-05-02 | Agensys Inc | NUCLEIC ACIDS AND CORRESPONDING PROTEINS NAMED 109P1D4 FOR THE TREATMENT AND DETECTION OF CANCER |
| EP1617840A4 (en) | 2003-05-01 | 2008-08-20 | Bristol Myers Squibb Co | PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS |
| EP1847531A4 (en) | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | PYRAZOLE DERIVATIVE |
| CN100526430C (zh) | 2005-10-19 | 2009-08-12 | 中国石油化工股份有限公司 | 一种生产清洁汽油的方法 |
| TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| KR20090007347A (ko) | 2006-03-22 | 2009-01-16 | 버텍스 파마슈티칼스 인코포레이티드 | 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제 |
| US20090253673A1 (en) | 2006-07-12 | 2009-10-08 | Min Ge | Substituted Pyrazoles as Ghrelin Receptor Antagonists |
| CN101583601B (zh) | 2007-01-17 | 2013-06-05 | 香港科技大学 | 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物 |
| US8153798B2 (en) | 2007-03-09 | 2012-04-10 | High Point Pharmaceuticals, Llc | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
| CN101366715A (zh) | 2007-08-15 | 2009-02-18 | 上海医药工业研究院 | 一种雷帕霉素组合物及其制备方法 |
| EP2222326B2 (en) | 2007-11-21 | 2015-02-25 | Vib Vzw | Inhibitors of malt1 proteolytic activity and uses thereof |
| TWI607996B (zh) | 2008-09-24 | 2017-12-11 | 巴地斯顏料化工廠 | 控制無脊椎害蟲之吡唑化合物 |
| WO2010039039A1 (en) | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| WO2011036885A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| WO2011161612A1 (en) | 2010-06-22 | 2011-12-29 | Basf Se | Process for preparing 4-hydroxypyridines |
| WO2012004217A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
| TW201236685A (en) | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
| JP6231085B2 (ja) | 2012-05-31 | 2017-11-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | アミノキナゾリン誘導体及びピリドピリミジン誘導体 |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| EA201590916A1 (ru) | 2012-11-09 | 2016-02-29 | Корнэлл Юниверсити | Низкомолекулярные ингибиторы malt1 |
| WO2014086478A1 (en) | 2012-12-03 | 2014-06-12 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of malt1 protease |
| MX2015008919A (es) | 2013-01-10 | 2015-10-22 | Gruenenthal Gmbh | Carboxamidas basadas en pirazolilo i como inhibidores del canal de calcio activado por liberacion de calcio (crac). |
| JP2015096499A (ja) | 2013-10-11 | 2015-05-21 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP6545197B2 (ja) * | 2014-05-28 | 2019-07-17 | ノバルティス アーゲー | 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用 |
| WO2015192081A1 (en) | 2014-06-13 | 2015-12-17 | Byrd, John C. | Biomarker for predicting response of cll to treatment with a btk inhibitor |
| WO2016005994A2 (en) | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires |
| MX2017001656A (es) | 2014-08-08 | 2017-07-24 | Pharmacyclics Llc | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. |
| BR112017004897A2 (pt) | 2014-09-10 | 2017-12-12 | Glaxosmithkline Ip Dev Ltd | compostos inovadores como inibidores rearranjados durante a transfecção (ret) |
| WO2016090382A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10835524B2 (en) | 2015-06-24 | 2020-11-17 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of pancreatic cancer and uses thereof |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| EP3374361A1 (en) * | 2015-11-13 | 2018-09-19 | Novartis AG | Novel pyrazolo pyrimidine derivatives |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| WO2017151786A1 (en) | 2016-03-01 | 2017-09-08 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| WO2018020474A1 (en) | 2016-07-29 | 2018-02-01 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| ES2856248T3 (es) | 2016-12-21 | 2021-09-27 | Acerta Pharma Bv | Inhibidores de imidazopirazina de la tirosina quinasa de Bruton |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| AU2017381433B2 (en) | 2016-12-21 | 2024-11-14 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| EP3576744A1 (en) | 2017-02-01 | 2019-12-11 | Medivir Aktiebolag | Therapeutic applications of malt1 inhibitors |
| EP3592731A4 (en) | 2017-03-08 | 2020-10-07 | Cornell University | MALT1 INHIBITORS AND THEIR USES |
| WO2018226150A1 (en) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
| KR20200105678A (ko) | 2017-12-28 | 2020-09-08 | 더 제너럴 하스피탈 코포레이션 | Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함 |
| EP3756268A1 (de) | 2018-02-23 | 2020-12-30 | Industrieanlagen-Betriebsgesellschaft mbH | Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen |
| EA202190055A1 (ru) | 2018-06-18 | 2021-04-23 | Янссен Фармацевтика Нв | Производные пиразола в качестве ингибиторов malt1 |
| AU2019289223B2 (en) | 2018-06-18 | 2023-09-21 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
| BR112021016400A2 (pt) | 2019-02-22 | 2021-10-13 | Janssen Pharmaceutica N.V. | Forma cristalina de mono-hidrato de 1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil.)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida |
| EP3927324A1 (en) | 2019-02-22 | 2021-12-29 | Janssen Pharmaceutica NV | Pharmaceutical formulations |
| US12404260B2 (en) | 2019-04-11 | 2025-09-02 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as MALT1 inhibitors |
| CA3162140A1 (en) | 2019-11-22 | 2021-05-27 | Janssen Pharmaceutica Nv | Methods for assessing efficacy of malt1 inhibitors using an nf-kb translocation assay |
| KR20220119037A (ko) | 2019-11-22 | 2022-08-26 | 얀센 파마슈티카 엔.브이. | MALT1 억제제의 효능 평가를 위한 NF-kB 조절 유전자 발현 분석 |
| WO2021138298A1 (en) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| JP2023539729A (ja) | 2020-08-21 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤の非晶質形態及びその製剤 |
| EP4199911A1 (en) | 2020-08-21 | 2023-06-28 | JANSSEN Pharmaceutica NV | Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acid |
| KR20230154227A (ko) | 2021-03-03 | 2023-11-07 | 얀센 파마슈티카 엔브이 | 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법 |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
-
2017
- 2017-12-19 TW TW106144535A patent/TWI795381B/zh not_active IP Right Cessation
- 2017-12-20 WO PCT/US2017/067516 patent/WO2018119036A1/en not_active Ceased
- 2017-12-20 EP EP17851862.7A patent/EP3558969B1/en active Active
- 2017-12-20 UA UAA201908268A patent/UA127920C2/uk unknown
- 2017-12-20 ES ES17851862T patent/ES2992411T3/es active Active
- 2017-12-20 MA MA047125A patent/MA47125A/fr unknown
- 2017-12-20 KR KR1020197021137A patent/KR102583317B1/ko active Active
- 2017-12-20 TN TNP/2019/000192A patent/TN2019000192A1/en unknown
- 2017-12-20 EA EA201991503A patent/EA201991503A1/ru unknown
- 2017-12-20 JP JP2019533465A patent/JP7138641B2/ja active Active
- 2017-12-20 CA CA3048027A patent/CA3048027A1/en active Pending
- 2017-12-20 AU AU2017382185A patent/AU2017382185C1/en not_active Ceased
- 2017-12-20 PE PE2019001288A patent/PE20191755A1/es unknown
- 2017-12-20 US US15/847,999 patent/US10954214B2/en active Active
- 2017-12-20 CN CN201780079706.3A patent/CN110214136A/zh active Pending
- 2017-12-20 BR BR112019012355A patent/BR112019012355A2/pt not_active Application Discontinuation
- 2017-12-20 MX MX2019007540A patent/MX392673B/es unknown
- 2017-12-21 UY UY0001037537A patent/UY37537A/es not_active Application Discontinuation
- 2017-12-21 AR ARP170103626A patent/AR110421A1/es not_active Application Discontinuation
-
2019
- 2019-05-31 PH PH12019501212A patent/PH12019501212A1/en unknown
- 2019-06-13 IL IL267343A patent/IL267343B2/en unknown
- 2019-06-19 CL CL2019001709A patent/CL2019001709A1/es unknown
- 2019-06-21 CO CONC2019/0006622A patent/CO2019006622A2/es unknown
- 2019-06-21 MX MX2022005827A patent/MX2022005827A/es unknown
-
2020
- 2020-11-25 US US17/104,081 patent/US12077521B2/en active Active
-
2022
- 2022-02-28 AU AU2022201352A patent/AU2022201352A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| PE20211411A1 (es) | Compuestos de anillo fusionado | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| EA201792421A1 (ru) | Амидозамещенные производные циклогексана | |
| EA202091711A1 (ru) | ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ | |
| PE20091556A1 (es) | Derivado heterociclico fusionado y su uso | |
| PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
| CL2007000601A1 (es) | Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa. | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
| PY1923494A (es) | Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida | |
| EA201100873A1 (ru) | Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания | |
| EA200802050A1 (ru) | Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов | |
| PE20151274A1 (es) | Inhibidores de erk y sus usos | |
| BR112016008080A8 (pt) | sal de composto heterocíclico contendo nitrogênio ou cristal do mesmo, composição farmacêutica e inibidor de flt3 | |
| PE20251292A1 (es) | Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| CY1120179T1 (el) | Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης | |
| UY40235A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| EA202091475A1 (ru) | ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА | |
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| EA201891315A1 (ru) | Твердые дисперсии, содержащие стимулятор sgc |